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Abstract

SIGNAL TRANSDUCTION EFFECTS INDUCED BY ERYTHROPOIETIN IN HNSCC
MODEL SYSTEM

By Shreya Kirit Desai, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2012

Major Director: Dr. Hiroshi Miyazaki, M.D., Ph.D.
Philips Institute, VCU School of Dentistry

Head and Neck Squamous Cell Carcinoma (HNSCC) is an epithelial skin cancer of
the upper aerodigestive tract, and is the sixth most common malignancy in the U.S.
HNSCC patients undergoing chemotherapy commonly develop anemia, a condition in
which the body lacks mature red blood cells (RBCs).

Erythropoietin (EPO) is a

systemically circulating hormone in the body that regulates the production of RBCs and is
applied to treat anemia. Recently, several studies implicated shortened life expectancy of
cancer patients by EPO administration. It may be due to an unexpected activation of
survival and proliferation pathways of cancer cells by EPO because of the presence of
xii

ectopically expressed erythropoietin receptor (EPOR) on the surface of cancer cells. The
current study tests the biological effects of EPO and EPOR in HNSCC. A shRNAmediated knockdown of the EPOR gene was applied to two specific cell lines, HN4 and its
metastatic derivative HN12. Knockdown of EPOR decreased proliferation in both HN4
and HN12 cells.

To our surprise, application of EPO to HN12 control cell line

downregulated proliferation in these high EPOR-expressing cells.
increased proliferation in a breast cancer cell line, MCF-7.

Conversely, EPO

Although EPO greatly

impacted HNSCC proliferation, no significant difference was found in migration of these
cells upon its application. It was indicated that the pathway responsible for proliferative
effects in HNSCC from EPOR association could be due to activation of the PI-3/Akt
pathway, judged by its phosphorylation of AKT. However, we need to further elucidate
the contradictive biological mechanisms of downregulation of HNSCC and upregulation of
MCF-7 proliferation. We also need to expand the number of screened cell lines and
confirm the relevance of our observation. Collected together, these findings confirm the
hypothesis that EPO and EPOR can impact HNSCC tumor progression, and that their
effects may vary among cancer types.

These results draw attention to the possible

detrimental use of EPO in cancer treatment, and its administration therefore, should be
reevaluated.

xiii

Introduction

1.1 Cancer
In 2012, about 570,000 people in the United States are expected to die from
cancer(19). The disease is responsible for approximately 25% of the total casualties per
year(19). It is also a worldwide health concern, claiming the lives of numerous individuals
due to its variability in development. Cancer is a disease involving the uncontrolled
growth of cells in the body. The high mortality rates and difficulty in successful treatment
of cancer lies in the ability of these cells to become mobile. Cancer cells metastasize,
spreading to nearby tissues and even distant organs(7). It is the metastatic potential of
cancer that allows the disease to become dangerous in the body, and is the cause of the
majority of related deaths(7).
Cancer is classified into five main categories by origin: carcinoma, sarcoma,
leukemia, lymphoma, and cancer of the central nervous system (CNS)(32). A carcinoma is
a cancer that is initiated in the skin and in the tissues that border internal organs(32). All
carcinomas are grouped by their histological appearance. For instance, ‘adenocarcinoma’
indicates that the cancer cells possess a glandular shape, whereas ‘squamous cell
carcinoma’ means cells of squamous, or flattened appearance. Sarcomas are cancers
originating from bone, and the tissues of muscle, fat, blood vessel, or cartilage(32). The two
1

main types of sarcoma are bone sarcoma and soft tissue sarcoma. Arising from bloodforming tissue, leukemia produces a large amount of abnormal white blood cells(32). These
cells develop by replacing the normally functioning pre-existing cells. Lymphoma is
cancer of a portion of the immune system called the lymphatic system. All lymphomas are
either classified as that of Hodgkin type or non-Hodgkin type(32). Hodgkin’s lymphoma
develops from a specific abnormal B cell lymphocyte, whereas non-Hodgkin’s lymphoma
can develop from abnormal B or T cell lymphocytes(32). CNS cancer originates in the
tissues of the brain and spinal cord. Most CNS cancers are categorized based on their
original location. The main sources of brain cancer are from cells called astrocytes, the
cerebellum, and the spinal cord(32).
Despite their origin, all cancers are believed to result from a sequence of genetic
alterations in normal cells, leading to a tumor phenotype.
composition, a newly transformed group of cells is formed(23).

Upon this change in
These cells develop

properties that often promote uncontrolled proliferation, survival, and invasion into
surrounding areas(23). Such physiological processes are tightly regulated under normal
conditions. However, an increase in these capacities can contribute to cancer metastasis.
This imbalance can be attributed to mutations in tumor-suppressor genes. These genes
normally keep cell growth controlled with their anti-proliferative properties.

Their

inactivation during cancer, however, allows proliferation to continue without regulation(23).
In addition to tumor-suppressor genes, the tumor phenotype can also result from an
inactivation in a second set of genes, proto-oncogenes(23). Under normal conditions, these
genes enhance proliferation. In cancerous conditions, proto-oncogenes have been found to
2

be overexpressed(23).

It is possible that changes in normal activity of tumor-suppressor

genes and proto-oncogenes act synergistically(23). A combination of genetic alterations in
both of these gene groups leads to aberrant protein expression, and phenotypic
characteristics associated with malignancy(23).
Genetic mutations observed in cancer are closely associated with environmental
risk factors including alcohol, smoking, and ultraviolet radiation exposure.

Chronic

alcohol consumption is one of the biggest predispositions to the development of cancer. A
distinct dose-response relationship can be observed between alcohol consumption and
cancer progression, especially in cancers of the upper aerodigestive tract(37,51). Ethanol has
been found to be the main compound in alcoholic beverages responsible for cancerous
effects. Acting as a solvent for entrance into the tissue mucosa, ethanol also facilitates
other carcinogens to penetrate easily(37). Through this process, carcinogens from tobacco
smoke, for instance, filter into the mucosa with the help of ethanol(37). Many in vitro and
in vitro studies show the toxic metabolite of alcohol, acetaldehyde, to possess direct
mutagenic effects(37). Acetaldehyde inhibits activity at many crucial DNA synthesis and
repair sites, disrupting the checkpoints involved in cell replication(37,51). Thus, ethanol and
acetaldehyde produce a cocarcinogenic effect leading to cancer.
The combined effect of alcohol and tobacco smoking increases the risk of cancer
more than each factor does alone(51). Some studies have found the effects of alcohol and
smoking to be multiplicative(51). The risk of cancer in the upper aerodigestive tract is the
highest among other cancers when considering both factors together. Approximately 75%
of cancers in this area can be attributed to alcohol and tobacco use at the same time(51).
3

The chemicals in tobacco smoke that are associated with cancer include nitrosamines,
benzo(a)pyrene, benzene, acrolein, and cadmium(35).

These compounds generate a

carcinogenic cocktail that produce damaging effects on DNA, similarly to alcoholic
components. Benzo(a)pyrene is the most damaging carcinogen of the mix, binding to cells
in the airways and organs of smokers(35). As a result, lung cancer is commonly linked to
smoking. Its risk is directly associated with the number of cigarettes smoked in males and
females(35). Other cancers attributed to smoking are cancers of the bladder, kidney, cervix,
oral cavity, stomach, pancreas and esophagus(35).

Figure 1.

The Incidence of Cancers Associated with Smoking. The risk

of men and women developing various cancers is related to smoking,
according to the percentages shown. The areas of the upper aerodigestive tract
are most frequently affected (Pichandi, et al, 2011)(35).

Ultraviolet (UV) radiation from the sun is a third risk factor for cancer, and exists
in three forms: UV-A, UV-B, and UV-C. Of these, UV-A and UV-B are associated
4

primarily with the development of skin cancer in humans(54). UV-B is a carcinogen that
can directly damage DNA through the formation of pyrimidine dimers. When DNA repair
mechanisms fail, mutations result and proceed through several cell divisions. UV-B also
forms highly reactive oxygen species, contributing to malignant DNA disruption.
Additionally, UV-A and UV-B radiation differentially express proteins involved in antiapoptosis. Due to this change, the normal DNA repair mechanisms to protect against such
radiation are interrupted. The main types of skin cancer resulting from ultraviolet radiation
include cutaneous malignant melanoma, basal cell carcinoma, and squamous cell
carcinoma(54). Although cancer due to UV radiation is preventable, the incidence of skin
cancer cases and mortality has steadily increased over the past decade(7,54).

1.2 Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common
malignancy in the United States(24). The incidence of HNSCC is high, presenting about
45,000 new cases each year(29). Classified as an epithelial skin cancer, HNSCC occurs in
the squamous mucosal lining of the upper aerodigestive tract in the following areas: the
nasal cavity, oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx(29). The
treatment and outcome of HNSCC is dependent upon the stage and location of the tumor.
Earlier stages (Stages I and II) of HNSCC are treated with a combination of surgical
resection, radiotherapy, and chemotherapy(29). More advanced stages (Stages III and IV)
are associated with poor survival rate, and are rarely cured(29). Those patients who present
with an advanced stage of the cancer commonly show signs of metastasis to the lymph
5

node(29). Although progress has been made for a more effective delivery of radiation to
patients, the five-year survival rate for HNSCC remains approximately 60-80% for stage I
cases, and 25-40% for stage IV cases(29). Advances in treatment planning of HNSCC
patients are underway with the use of procedures such as hyperfractionation. This form of
treatment allows the delivery of radiation at a more frequent, lower dose per day(29).
Administration of such recurrent treatment reduces the risk of tumor re-growth(29).
Additionally, Human papillomavirus (HPV) has shown to play a pathological role in
HNSCC tumorigenesis(48). HPV DNA was positively detected in several oropharyngeal
tumors in HNSCC over the past decade, and is classified as a risk factor for the cancer(33).
Those cancers that have been associated with HPV positive DNA require a separate
treatment strategy from HNSCC as described previously(33).

6

Figure 2.

Human Anatomical Regions Affected by HNSCC. The

indicated regions of the upper aerodigestive tract are lined by squamous
mucosa, and are affected by HNSCC (Vokes et al, 1993)(53).

1.3 Anemia and Tumor Hypoxia
As a direct result of chemotherapy, radiation, and other forms of myelosuppressive
therapy for cancer treatment, HNSCC along with other cancer patients often develop a
condition known as anemia. Anemia is a clinical condition in which the body is deficient
in functional mature red blood cells (RBCs), leading to decreased oxygen-carrying
capacity(20). Anemia is grouped into iron-deficiency anemia, pernicious anemia, folic aciddeficiency anemia, hemolytic anemia, and sickle cell anemia. Those associated with
inadequate intake or absorption of a vitamin or mineral include iron-deficiency anemia due
to a lack of iron, pernicious anemia from a lack of vitamin B12, and folic acid-deficiency
7

anemia from a lack of folic acid. Deficiency in iron is the most common cause of anemia
in the world(20). Hemolytic anemia is an inherited disease that involves the premature
destruction of red blood cells. Sickle-cell anemia is also a genetically associated condition
in which the red blood cells become sickle-shaped, caused by an abnormal type of
hemoglobin.
Anemia can be caused by an insufficient production of a blood protein called
hemoglobin(20). Hemoglobin is the metalloprotein in RBCs that serves as the body’s
primary oxygen transporter. The hemoglobin structure is a tetrameric unit with a pair of
dimeric polypeptide chains(40). These polypeptide chains are α-globins and β-globins, and
each of these four polypeptides has a central space into which a heme group binds,
rendering the name ‘metalloprotein’(40). The heme group is an iron protoporphyrin IX
molecule, and is commonly found in the ferrous (FeII) valence state under physiological
conditions(40). The primary role of hemoglobin is to carry oxygen from the lungs to the
tissues of systemic organs(40).

Development of anemia can cause fatigue, dizziness,

headache, and impaired cognitive function due to decreased oxygen transport by
hemoglobin(12).
Cancer patients especially require fully functioning organs to overcome the
debilitating side effects of radiation treatment, one of which is risk of anemia. Therefore,
an adequate amount of hemoglobin is essential to maintain oxygen transport in cancer
patients. Anemia may cause impaired quality of life and increased blood transfusion
requirements in these individuals(12). A hemoglobin level less than approximately 12 g/dL
dropping from a normal range of 13-17 g/dL, commonly results in these unfavorable
8

outcomes, according to several clinical studies(12,46,50). Maintaining hemoglobin levels
above this threshold is critical during chemotherapy and radiation treatment of cancer
patients.
Tumor hypoxia, or depletion of oxygen levels associated with solid tumor
development, is caused by imbalanced oxygen supply and consumption(47).

Anemia-

related hypoxia, specifically, results from decreased oxygen transport in the blood as a
result of radiation and/or chemotherapy effects(47). Therefore, less oxygen is supplied to
tumor cells during such cancer treatment. In response to this hypoxic stress environment,
tumor cells develop compensatory mechanisms including resistance to radiation and
chemotherapy, leading to eventual metastasis(47). The cells overcome oxygen deprivation
through increased proliferation, migration, and invasion into local and regional sites,
enhancing tumorigenesis(47). A key trigger for these processes is induction of hypoxia
inducible factor-1 (HIF-1), which directly responds to a decline in cellular oxygen
levels(47). HIF-1 is a transcription factor that further activates genes involved in oxygen
delivery, energy preservation, and events promoting tumor cell survival and spread(47).
Therefore, activation of HIF-1 and associated transcriptional changes can promote cancer
progression. Efforts to correct anemia-related hypoxia are currently being studied to
provide a more beneficial outcome for cancer patients(47).

1.4 Erythropoietin
Erythropoietin (EPO) is a 30.4-kDa acidic glycoprotein hormone that regulates
RBC production and differentiation through a process known as erythropoiesis in the bone
9

marrow(22).

Erythropoiesis is defined as the progression of immature RBCs from a

progenitor state to a mature, functional form. In human adults, 2 x 1011 red blood cells are
produced each day during erythropoiesis(20).

Along with RBC differentiation, EPO is

known to prevent apoptosis of RBC precursors, and has been shown to promote cellular
proliferation and survival(11,20,22,27).

Furthermore, EPO has the potential to induce

angiogenesis, or the growth of new blood vessels through multiple regulatory factors,
including vascular endothelial growth factor (VEGF).

VEGF is essential in the

physiological process of angiogenesis, and is commonly secreted by endothelial cells(27).

1.4.1 Structure of Erythropoietin
The peptide core of EPO is comprised of 165 amino acid residues with four
oligosaccharide chains. The carbohydrate portion of the peptide core is made up of three
N-linked glycans and one O-linked glycan. Glycosylation, or addition of sugars to the
protein, adds stability and slows the metabolic clearance of the hormone, enabling it to
work longer in the body. The molecular structure of EPO consists of a four-membered
amphipathic α-helical bundle: αA, αB, αC, and αD in order from the N-terminus to the Cterminus. A disulfide bond connects the αA and αD helices between two cysteine residues,
Cys 7 and Cys 161, generating a long loop. Conversely, only a short loop holds together
the αB and αC helices(22).

10

Figure 3.

Structure of Erythropoietin. The four α-helices of

erythropoietin are shown in blue and interconnected by red loops. The longest
of the loops is that between the αA and αD subunits connected by disulfide
bonds, S1 and S2 (figure modified according to Cheetham et al, 1998)(6).

The human EPO gene is located on the long (q) arm of chromosome 7 at position
22, and consists of five exons and four introns with no splice variants reported thus far.
The hormone is produced by the cleavage of its 193-amino acid prohormone.
Sequentially, a 28-amino acid sequence is cleaved from the prohormone to generate the
mature 165-amino acid hormone as functional EPO.
11

Hypoxia response elements are

located on the 3’ enhancer end of the EPO gene. HIF-1 binds to these elements when
oxygen levels are low.

Activated by oxygen deprivation, such transcription factors

promote RBC proliferation when bound to the hypoxia response elements(22).

1.4.2 Erythropoietin Production
EPO is produced by peritubular capillary cells in the kidney through a negative
feedback mechanism in response to low oxygen levels. The liver also produces EPO in
response to hypoxic conditions(20). The negative feedback mechanism is activated based
on a change in the oxygen pressure (pO2) in the peripheral tissues. The pO2 level is a
combination of hemoglobin concentration and the oxygen affinity of the existing
hemoglobin. When the kidney senses a drop in pO2 in the tissues, or a deficiency in
erythrocyte production, EPO is secreted to restore basal pO2 levels(22). On the other hand,
a high pO2 level decreases the stimulus for EPO production(20).
The secreted EPO flows through the bloodstream and is carried to the bone
marrow, and acts on precursor cells called Erythrocyte-Colony Forming Units (CFU-E).
These cells are highly responsive to EPO, even under low EPO concentrations(20). CFU-E
cells develop into erythroblasts and then reticulocytes that finally mature into RBCs in the
peripheral circulation. The CFU-E cells produce about 8-80 enucleate mature erythrocytes
after several cell division cycles. This process usually takes 7-8 days for human RBCs,
each cell possessing an average lifespan of 120 days. After maturation, the erythrocytes
are continuously destroyed and formed through a balance of GATA-binding factor 1
(GATA-1) and caspases. GATA-1 is an erythroid transcription factor that is important in
12

the development of RBCs. Cleavage of GATA-1 by a group of protein-degrading enzymes
known as caspases arrests erythroid maturation during differentiation(22).

Figure 4.

The Production of Erythropoietin. Low pO2 stimulates EPO

production by the kidney and promotes RBC differentiation through a negative
feedback mechanism (Hodges et al, 2007)(20).

1.5 Erythropoietin Receptor
Erythropoietin receptor (EPOR) is a 59 kDa peptide encoded by the EPOR gene
and is a member of the type I cytokine receptor superfamily. The EPOR gene is located on
13

the short (p) arm of chromosome 19 at position 13, and consists of 8 exons. RBC
production is exerted by the ligation of EPO to EPOR. This ligand-receptor binding event
is indispensible for cellular proliferation and survival of RBCs. A conserved sequence
motif of the EPOR gene, Trp-Ser-Xaa-Trp-Ser (WSXWS domain) existing just outside of
the transmembrane domain of the receptor, aids in signal transduction and ligand binding
of EPO. This motif also ensures complete protein folding and cell surface expression of
EPOR(8).
The structure of EPOR consists of three major domains:

an extracellular,

transmembrane, and intracellular domain. The extracellular domain is composed of two
subunits, D1 and D2, which form an L shape. This L-shaped portion is secured by two
disulfide bonds between four conserved cysteine residues, Cys67, Cys83, Cys28, and
Cys38. The transmembrane domain is composed of a single hydrophobic portion, whereas
the intracellular domain consists of non-enzymatic segments occupied with the amino
acids proline, glutamate, and aspartate(8).
Mutations in the EPOR gene can be associated with various disorders such as
familial erythrocytosis and erythropoietin-independent erythroid proliferation.

For

example, a point mutation in the EPOR gene delays intracellular transport of EPOR similar
to erythropoietin-independent activation of EPOR.

The hereditary disease, familial

erythrocytosis, is an autosomal dominant disorder caused by a deletion mutation in exon 8
of the EPOR gene. This mutation generates a truncated construct of the peptide encoded
by the gene via introduction of a premature termination codon.

The phenotype is

characterized by low plasma EPO levels and increased sensitivity to EPO. One study
14

reports that the truncated receptor linked to familial erythrocytosis was sensitive to lower
levels of EPO when compared to the wild type form of the receptor.

Familial

erythrocytosis produces autonomous red blood cell production as a result of this increased
sensitivity to a low basal level of EPO(3). Polycythemia vera is a disorder that can be
acquired due to an amino acid substitution, V617F, in the Janus family protein tyrosine
kinase 2 (JAK2) molecule(20). JAK2 is a molecule that when activated contributes to
differentiation and survival of RBCs.

In polycythemia vera, JAK2 is constitutively

activated due to the mutation, leading to an excessive amount of RBC production. This
condition differs from familial erythrocytosis in that RBC production can proceed in the
absence of EPO(20).

1.6 Receptor Tyrosine Kinases
Kinases are enzymes that transfer a phosphate group from a donor molecule to a target
molecule. The family of Receptor Tyrosine Kinases (RTKs) possesses an intrinsic enzyme
activity dissimilar to members of the cytokine superfamily, including EPOR. RTKs are a
group of cell surface receptors that respond to cytokines, growth factors, hormones, and a
wide variety of ligands. A majority of these RTKs exist on the surface of lipid bilayers as
monomeric subunits, but some can exist as trimeric complexes. RTKs are composed of
three different portions which include: an extracellular N-terminal domain, a single
hydrophobic α-helical transmembrane domain, and a carboxyl terminal domain.

The

extracellular N-terminal domain is termed the ligand-binding site, and the C-terminal
domain is termed the catalytic site that facilitates kinase activity for transphosphorylation.
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RTKs are well known to play an important role in diverse cell activities such as growth,
differentiation, and angiogenesis. Mutant forms of RTKs can send growth signals to
stimulate proliferation without the presence of the ligand. Deletion of the extracellular
ligand-binding domain for example in the epidermal growth factor (EGF) receptor
produces a mutant form of the receptor that is constitutively active without presence of
EGF(21). Through their mutant forms, RTKs have the potential to become activated even in
the absence of associated growth factors, which can possibly facilitate unregulated cancer
progression.

Figure 5.

Receptor Tyrosine Kinases Exhibit Intrinsic Enzyme Activity. The

ability to transphosphorylate (trans-autophosphorylation) separates receptor tyrosine
kinases from other enzymatic molecules. The C-terminal domain facilitates such
phosphorylation to take place to establish the active form of the receptor (Hubbard, et
al, 1998)(21).
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RTKs are subdivided into five major families including the EGF receptor family,
fibroblast growth factor (FGF) receptor family, RET receptor family, Eph receptor family,
and VEGF receptor family. The EGF receptor family is mostly responsible for processes
including wound healing, growth, and development. The FGF receptor family performs
similar activities involving embryogenic development. The FGF receptor utilizes the help
of heparin sulfate, a proteoglycan that assists in maintenance of the extracellular matrix.
Many physiological disorders associated with the EGF and FGF receptor family are
associated with irregularities in bone formation. The Eph receptor family contains the
largest amount of RTKs and promotes processes involved in axon growth. The VEGF
receptor family plays a major role in the permeability of blood vessels, growth of
endothelial cells, and angiogenesis(21). Members of these five families of RTKs possess
the ability of transphosphorylation. Although such intrinsic kinase activity is not present
in EPOR, recent observations show that tyrosine phosphorylation plays an important role
in hematopoietic signaling from the EPOR cytokine receptor(30). Furthermore, several
members of the VEGF receptor family have been found to associate with EPOR to
promote angiogenesis and possible neovascularization of tumors.
In order for EPOR to transduce signals from EPO by phosphorylating its target
proteins, EPOR needs to dimerize and bind to cytoplasmic tyrosine kinases to activate
subsequent gene transcription events. The cytoplasmic tyrosine kinase, JAK2, becomes
activated upon ligation of EPO to EPOR.
phosphorylates EPOR(30).

Upon ligand-binding, JAK2 binds to and

From here, adaptor proteins can further interact with the
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receptor to activate various signal transduction pathways that maintain the survival,
differentiation, and proliferation of RBCs.

1.7 GPCRs
G-protein coupled receptors (GPCRs) are the largest and most diverse family of
membrane proteins responsible for transduction of extracellular stimuli into intracellular
signals.

They comprise almost 800 genes in the human genome, and are found only in

eukaryotic organisms(9). These proteins have a great relevance in pharmaceutical research,
as many GPCR family members are used as drug targets and are clinically available(9). All
GPCRs comprise of seven membrane-spanning α helices, three intracellular loops, three
extracellular loops, an extracellular N-terminus, and an intracellular C-terminus(17).
Based on their homology in sequence and similarity in function to well-known
molecules, all GPCRs are classified into five families: the rhodopsin family, secretin
family, adhesion family, glutamate family, and frizzled/taste2 family(17).

These five

families together form the GRAFS classification system. The diversity among GPCRs is
tremendous, but they all possess certain common structural characteristics.
GPCRs respond to signals such as pheromones, odors, proteases, peptides,
glycoprotein hormones, and ions that act as ligands(9). Ligand binding activates the GPCR,
and induces a conformational change in the receptor.

The conformational change

promotes signal transduction through an interaction of heterotrimeric G proteins (GTPbinding proteins) with the intracellular side of the GPCR(9). The G proteins are known as
heterotrimers based on their three subunit complex: Gα, Gβ, and Gγ. The Gα portion of
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the heterotrimer exists as the guanosine diphosphate (GDP) bound form in its inactive
state. Upon binding of a signaling molecule to the extracellular domain of the GPCR, a
conformational change takes place in the receptor(9). The receptor interacts with the G
protein present in this location. In this sequential process, Gα releases bound GDP for
guanosine triphosphate (GTP)(5). The exchange promotes the dissociation of Gα-GTP
from the β and γ subunit complex, which were previously tightly bound as one unit. Both
complexes of Gα and Gβγ not only dissociate from each other, but from the receptor as
well(5).

The GTP-bound form represents an activated complex. At this time, each

diverging complex has the ability to initiate cellular responses by activating intracellular
signaling molecules.

The dissociation of Gα from Gβγ is accelerated by guanine

nucleotide exchange factors (GEFs)(42). Following these events, the GTPase activity of Gα
subsequently switches back to its GTP-bound state from its GDP-bound state through
hydrolysis of the phosphate group(5). This is the deactivated form of Gα. A reassociation
of Gα with the Gβγ complex occurs from the hydrolysis step(5). Although most of this
reassociation process can be attributed to the intrinsic GTP hydrolysis ability of G proteins,
the deactivation process is also enhanced by GTPase activating proteins (GAPs) that are
essential for the hydrolysis step(42). At this time, the hetrotrimeric complex is ready to
once again interact with the receptor to reinitiate the next activation cycle.
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Figure 6.

Activation of the G-Protein Coupled Receptor Mechanism by

Binding of Extracellular Agonists. Upon GPCR activation by the ligation of an
extracellular agonist, the Gα subunit of the heterotrimeric G protein complex
dissociates from the Gβ and Gγ subunits. The G protein switches from its
inactive GDP-bound state to an active GTP state, activating downstream signal
effector molecules. GEFs are essential for the dissociation of Gα from Gβγ.
GAPs are important in forming the reassociated complex (figure modified
according to Li et al, 2007)(26).
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The complexity and selectivity among GPCR family members is attributed to the
diversity in the Gα class activation mechanisms. The Gα subunit is subdivided into five
major classes: Gαs, Gαi, Gαo, Gαq/11, and Gα12/13. The Gαs class is mainly responsible for
stimulating the enzyme adenylyl cyclase, which converts ATP into cyclic AMP (cAMP).
cAMP is a second messenger molecule which activates protein kinase A (PKA) as its
effector molecule. Conversely, the Gαi and Gαo classes perform the opposite function.
They inhibit adenylyl cyclase, therefore downregulating the production of cAMP(10).
Molecules associated with regulation by the Gαi/o classes include various ion channels,
phospholipase C (PLC), and phosphatidylinositol-3 kinases (PI3-K). The Gαq/11 class
consists of Gαq members and G11 members, including both due to their similarity in
function. The molecule most commonly associated with the Gαq/11 class is phospholipase
C-β.

Phospholipase C-β once activated goes on to break down phospholipids

phosphatidylinositol-bisphosphate (PIP2) into diacylglycerol (DAG) and inositoltriphosphate (IP3) to subsequently initiate protein kinase C (PKC) activation. DAG and IP3
together are responsible for the opening of Ca2+ channels and play an important role in
muscle contraction and relaxation(10). Finally, the Gα12/13 class is a combined class of Gα12
and Gα13 subunits that activate the small GTPase, Rho. Rho then proceeds to activate
signaling molecules such as phospholipase D that are responsible for maintenance of the
cytoskeleton(36).
The variation in Gα classes is due to alternative splicing of genes that encode the
subunit. These Gα classes are most commonly activated via phosphorylation of kinases
associated with a receptor signal. Concurrently, one or more than one class of Gα proteins
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can be switched on. For example, a single receptor signal has the ability to activate the
Gαq/11 as well as the Gα12/13 simultaneously. Furthermore, receptor-associated kinases may
switch their activation of a particular class to another class, turning on even more effector
molecules. The receptors responsible for activating the proteins often prefer specific splice
variants of Gα, increasing the variation associated with Gα signaling.

Overall, the

specificity involved in Gα subunit activation should be evaluated individually according to
each ligand-receptor mechanism(10).
Although the Gα subunit of the heterotrimeric complex is responsible for the
majority of cellular signaling associated with G proteins, the Gβγ subunit has shown to
play critical roles in downstream signal activation in many pathways. The Gβγ complex is
linked to the opening of various ion channels, especially the inward rectifier potassium
channels (GIRKs). The opening of these channels allows the cell to become permeable to
potassium ions, leading to cellular hyperpolarization.

Furthermore, Gβγ activates

phospholipase-β and phosphatidylinositol 3-kinase (PI3-K), similar to the Gαq/11 class(5).
Several G-protein independent mechanisms activate important intracellular
signaling pathways. In these circumstances, G proteins perform their function through
other effector proteins, such as G-protein kinases (GRKs). GRKs directly regulate GPCR
function via phosphorylation, are important for GPCR desensitization, and activate
pathways such as the classical mitogen-activated protein kinase (MAPK) pathways.
Activation of the MAPK pathway leads to activation of extracellular-signal-related-kinase
(ERK) molecule, contributing to cellular growth.

Receptor tyrosine kinases also

demonstrate activation through G-protein independent signaling(41).
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G Protein

Effect of Activation

Gαs

Adenylyl cyclase stimulation

Gαi/o

Adenylyl cyclase inhibition

Gαq

Activation of phospholipase β (PLC-β); breakdown of PIP2 into
IP3 and DAG

Gα12/13
Gβγ

Table 1.

Activation of Rho
Activation of inward rectifier potassium channels (GIRKs);
activation of PLC-β

Signaling Molecules Activated by G Protein Subunits.

Each G protein subunit complex activates its own set of intracellular messengers
that can act alone, or crosstalk with another independent pathway to produce a
specific cellular function(10).

GPCRs are known to play important roles in several signal transduction
mechanisms including those involved with cell growth, proliferation, motility, and
differentiation.

Research suggests the involvement of GPCRs in cancer progression.

Small GTPase proteins associated with the receptors, like the family of Ras proteins, are
activated by extracellular signals that can initiate cancer cell growth, survival, and
migration(9). Today, activated mutations in Ras are among the most common in cancer.
Amplification of Ras genes leads to constitutive activation of several cancer signaling
pathways(34). In addition, GPCR-activated signaling pathways can crosstalk with other
mechanisms, without the involvement of G proteins as mentioned before.

These

interactions often involve pathways regulated by tyrosine kinases. In this regard, tyrosine
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kinase pathways activated by EPO/EPOR binding can also network with mitogenic
pathways turned on by GPCR activation.

This crosstalk leads to cancer cell cycle

progression, inducing invasiveness and eventual metastasis(9).
Cellular responses associated with GPCRs are an integration of several signaling
pathways, not just one transduction cascade.

Many GPCRs are associated with the

survival of tumor cells. The combination of mechanisms and possible link to cancer
contributes to the intricacy of pathways involved in cancer growth. EPO’s binding to
EPOR has shown to activate many GPCR-relating pathways together with others. In
particular, activation of the EPO/EPOR mechanism is linked to Ras activation which leads
to a pronounced migration and proliferation of cancer cells(13,16,25,30,41).
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Figure 7.

Pathways Activated by Gα subunits Associated with Cancer.

Upon dissociation of the Gα subunit from the Gβγ subunits, the Gα complex
proceeds to activate various intracellular signaling pathways that can potentially
play a role in cancer progression (Steinhoff et al, 2005)(44).

1.8 The Erythropoietin-Erythropoietin Receptor Signaling Mechanism
As previously mentioned, EPO serves as a ligand molecule for EPOR, expressed on
the surface of erythroid progenitor cells. When EPO binds to EPOR during hypoxia,
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erythrocyte differentiation, survival, and proliferation are promoted. Prior to the binding
event, EPOR exists as a dimer. When EPO binds, a conformational change is induced,
recruiting JAK2 molecules to bind to the cytoplasmic tail of EPOR.

These JAK2

molecules are activated upon phosphorylation. JAK2 phosphorylates itself in a process
called transphosphorylation. It simultaneously phosphorylates tyrosine residues located on
the cytoplasmic domain of EPOR. These phosphorylated residues serve as docking sites
for various signaling molecules through Src homology 2 (SH2) domains, including the
signal transducer and activator of transcription 5 molecule (STAT5) on EPOR. STAT5
binds to the cytoplasmic domain of EPOR and is also transphosphorylated.

It then

homodimerizes and becomes translocated to the nucleus to activate transcription of
downstream target genes such as Bcl-XL, an anti-apoptotic molecule(38).
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Activation of the JAK-STAT Pathway. EPO binding to EPOR

recruits JAK2 to phosphorylate tyrosine residues on the cytoplasmic tail. JAK2
proceeds to phosphorylate the recruited STAT5 transcription factor. STAT5
becomes phosphorylated, homodimerizes, and is translocated to the nucleus to
activate target gene transcription (figure modified according to Swameye et al,
2003)(45).
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1.9

Cellular Proliferation and Survival Pathways Activated by the EPO/EPOR

Mechanism
In addition to the JAK2-STAT5 mechanism, several proliferation, survival, and
anti-apoptotic pathways can become activated upon EPO/EPOR binding, such as the PI-3
kinase pathway involving activation of Akt, or protein kinase B. The activation of the PI-3
kinase/Akt pathway is termed an anti-apoptotic, or pro-survival process.

Akt is a

prosurvival molecule known to inactivate proapoptotic molecules, i.e., caspase 9, BAD, by
phosphorylation, and also retain the FOXO transcription factors responsible for inhibiting
activation of anti-apoptotic molecules, i.e., Bim. It can also phosphorylate inhibitor of
nuclear factor kappa-B kinase subunit beta (IκB-β), which further activates nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)(38).
Activation of the canonical MAPK/ERK pathway can be achieved by EPO/EPOR
binding as well. The MAPK pathway is termed a pro-cell proliferation and migration
process. When EPO binds to EPOR, Ras homolog gene family member A (RhoA) can be
phosphorylated. RhoA is a member of the PKC family, made up of serine-threonine
kinases. This PKC molecule proceeds to activate Raf1, which directly phosphorylates
MEK 1 and 2. These MEKs phosphorylate ERKs on the threonine and tyrosine residues
on the EPOR cytoplasmic tail to activate final effectors for initiation of gene
transcription(38).
These pathways, however, have been proposed to become activated in cancerrelated processes as a result of EPOR expression on the surface of tumor cells. Fu, et al
demonstrates constitutive activation of EPOR to promote breast cancer cell proliferation
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and migration through the MAPK pathway(13). A separate study also conducted in breast
cancer concludes for EPO to activate more than one signaling cascade, including JAK2STAT5, PI3-K/Akt, as well as the MAPK pathway.

Activation of these pathways

increased the migration, invasion, and colony formation in this study, enhancing
tumorigenesis(41). Simultaneous activation and crosstalk of these pathways can contribute
to the complexity associated with EPO/EPOR binding. The molecular mechanism has the
potential to promote in vivo tumor invasiveness, and therefore exacerbate the effects of
cancer in patients.
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Figure 9.

Survival and Proliferation Pathways Promote Tumor Progression.

Activation of these pathways could lead towards tumor malignancy and thereby
reverse the positive effects of EPO administration during cancer treatment (figure
modified according to Hadland et al, 2009)(15).
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1.10 The Angiogenic Potential of Erythropoietin
Angiogenesis is the development of new blood vessels from pre-existing vessels.
An angiogenic response is initiated in response to developmental events such as wound
healing, and other immune system processes. Angiogenesis, however, can also support
abnormal processes, i.e., tumor progression, towards metastasis.

A new, branching

network of blood vessels is necessary for a tumor to become metastatic. The processes
involved in normal and abnormal angiogenesis are not well elucidated, and have been
reported to be differentially regulated. Solid tumors can be established through the supply
of oxygen and nutrients to tissues during angiogenesis. New blood vessels promote the
formation of additional vessels through an ongoing process to promote tumor growth and
invasion.
Families of angiogensis-stimulating molecules are indispensable for initiation of
angiogenesis. These molecules are proteins that are secreted by normal and tumor cells as
signals to initiate the process. Such activators include: the VEGF family, EGF family,
bFGF (basic fibroblast growth factor) family, and tumor necrosis factor alpha (TNF-α).
When these molecules are released from tumor cells, a signal is released into the nucleus
of the endothelial cells lining the blood vessels. Genes are activated inside the nucleus,
and the products of these genes stimulate growth of new endothelial cells(32).
Simultaneously, the new endothelial cells produced secrete enzymes known as
matrix metalloproteinases. These enzymes play critical roles in the breakdown of the
extracellular matrix. When this matrix is disrupted, the cells become free to migrate

31

towards other tissues.

These migrated endothelial cells eventually align and become

structured into an organized network of blood vessels(32).
According to its activation, angiogenesis possesses the same trigger as that of EPO
secretion from the kidney(32). EPO has been reported to play a role in angiogenesis in the
mouse embryo and during the wound healing process in previous studies(18). Its role in
tumor angiogenesis has been implicated, however, its modulation of neovascularization
has not been established(18).

1.11 Contradictory Evidence from the Literature

1.11.1 Benefits of Erythropoietin for Treatment of Anemia
Erythropoiesis-stimulating agents (ESAs) are frequently used as a therapeutic
intervention method for cancer patients experiencing radiotherapy and chemotherapyrelated anemia and tumor hypoxia.

ESAs are a recombinant, synthetic form of the

endogenous form of EPO. Prior to their approval, the only option for treatment of anemia
was a blood transfusion. Today, the administration of ESAs in hospitals prevents many
patients from resorting to this solution. ESAs in current use in the clinical setting include:
epoetin-α, epoetin-β, and darbepoietin-α(11). Epoetin-α is the first approved ESA by the
FDA, and is a highly effective stimulant for erythropoiesis in the hospital setting(12,46,50).
Improvements are underway to enhance the serum half-lives of these ESAs,
increasing the biological potency of the drugs.

Darbepoietin-α is the most recently

approved ESA in 2001, and possesses a longer elimination half-life than epoetin-α and
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epoetin-β. Enhanced bioactivity of this ESA comes from an addition of two N-linked
carbohydrate chains, increasing its half-life threefold compared with epoetin-α(12). Overall,
exogenous use of ESAs has been shown to replenish hemoglobin levels and improve
anemia in patients(12,46,50).
In addition, clinical studies evaluating quality of life (QoL) with EPO
administration showed drastic improvement in energy levels in cancer patients with anemia
(12,50)

.

A study conducted in ovarian cancer patients receiving platinum-based

chemotherapy showed a significant correlation between upregulated hemoglobin levels and
improvement of QoL scores. The increased hemoglobin levels resulted in a decrease risk
of blood transfusion among patients enrolled in the study(50).

1.9.2 Erythropoietin: A Source of Controversy for Treatment
Contrary to the beneficial effects of EPO for treatment of anemia, two independent
European trials raised safety concern for its use when ESAs were found to decrease overall
patient survival. Due to these striking findings, the Oncologic Drugs Advisory Committee
(ODAC) convened to reassess the risks and benefits of ESAs when five clinical trials
(BEST, ENHANCE, AMG-20010103, AMG-20000161, and EPO-CAN-20) also
confirmed decreased survival.

Restrictions on ESAs were placed by the Centers for

Medicare and Medicaid Services the same year that the ODAC met(3).
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Therapy

Type of
Cancer

Adverse Outcome

Chemotherapy

Breast Cancer

Adverse Outcome for ESA Arm

AMG-20010161
(n = 344)

Chemotherapy

Lymphoid
Malignancy

ENHANCE
(n= 351)

Radiotherapy

Head and Neck
Cancer

Decreased 12-month
overall survival
Decreased 5-year locoregional
progression-free survival and
overall survival

EPO-CAN-20
(n= 70)

None

Non-Small Cell
Lung Cancer

Decreased overall
survival

AMG-20010130
(n = 989)

None

Non-Myeloid
Malignancy

Decreased overall
survival

Study (n)
BEST
(n = 933)

Table 2.

The Adverse Effects of ESAs in Clinical Trials. Several ESA clinical

trials show increased need for blood transfusion, low patient survival, and low
quality of life (N = number of patients enrolled in the study)(3).

The negative results of using ESAs in the clinical setting urged scientists to
reevaluate the effects of EPO by studying the EPO/EPOR molecular mechanism in vitro.
Expression levels of both EPO and EPOR on nonhematopoietic cells have recently been
found to be present by numerous studies.

Several of these sources show increased

expression of both in cancer cells. Studies conducted in breast and lung cancer have most
frequently shown upregulation of either EPO or EPOR, or both(13,25,39,41).
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A study conducted in breast cancer cells determined an overexpressed EPOR
construct to be constitutively active. Furthermore, these expression levels were found to
be linked with an increased proliferation and migration of the cells through activation of
the MAPK-ERK pathway(13).

A similar finding confirmed these results in a study

conducted with HNSCC. In this case, EPO and EPOR were found to be expressed in 95%
and 99% of the cancer cell lines, respectively(52). The results of these molecular studies are
consistent with outcomes of clinical trials that show the detrimental effects of EPO in
cancer treatment.

The presence of EPO/EPOR on tumor cells confirms that their

expression is not limited to hematopoietic cells. Activation of the EPO/EPOR mechanism
could therefore act as a direct enhancer of tumor growth, survival, and possibly
angiogenesis through activation, and possibly crosstalk of the signaling pathways
previously proposed.

1.12 Aim of the Present Study
The evidence surrounding the interaction of EPO with EPOR in tumor development
remains inconclusive. The conclusions made by clinical and molecular studies concerning
EPO’s role in tumor inhibition vary. According to previous studies conducted, its negative
biological effect could result from the increased expression of EPOR in various cancers.
The rationale for this project is to further elucidate the role of EPOR expression in HNSCC
cells, the biological effect of EPO in vitro in these cells, and to therefore verify the safety
and risk of EPO when administered to head and neck cancer patients who are suffering
from severe anemia. The hypothesis of this study is that EPOR is expressed on the surface
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of some HNSCC cells, and therefore activates the EPO/EPOR signal transduction
mechanism that may enhance cancer development related processes, such as cell survival,
motility, proliferation, and possibly angiogenesis.
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Materials and Methods

2.1 Cell Lines and Culture

2.1.1 Cell Line Preparation
HN4 and HN12 human head and neck squamous carcinoma cells (HNSCC) were
obtained from (insert) from the same patient. The cells were placed in a 37°C water bath
to thaw after removal from a -80°C storage location. The cells were then suspended in a
solution of 10 mL of Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech,
Manassas, VA), 10% Fetal Bovine Serum (FBS), and antibiotics (100 U/mL penicillin, 100
µg/mL streptomycin, and 100 µg/mL puromycin), and placed on a 10 cm tissue culture
plate. Each tissue culture plate was then placed in a humidified incubator at 37°C with a
10% CO2 control and 90% air to allow for growth. The cells were washed with PBS and
cultured in the same solution of media every two days for maintenance until needed.

2.1.2 Lenti-EPOR shRNA Infection
Cells were infected with the GeneCopoeia® HIV-based lentiviral expression vector
system. The advantage of this transfection system is a high knockdown efficiency against
target mRNA transcripts. 2.5 µg of lentiviral shRNA expression plasmid and 5.0 µL of
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Lenti-Pac HIV mix were diluted into 200 µL of Opti-MEM® I. 15 µL of EndoFectin Lenti
was diluted into 200 µL of Opti-MEM® I. The diluted EndoFectin Lenti reagent was
added to the plasmid DNA solution and incubated for 15 minutes at room temperature.
This solution was added to plated GeneCopoeia® 293Ta lentiviral packaging cells, and
incubated overnight.

The solution was replaced with 10% FBS DMEM solution

supplemented with streptomycin and penicillin antibiotics, and incubation continued. The
lentivirus culture medium was then harvested 48 hours later, and centrifuged 500 x g for
10 minutes. Harvested lentiviral particles were then stored at -80°C until further usage.
The target cells were then transduced with the lentiviral particles by preparing 0.5 mL of
the virus suspension diluted in 10% FBS DMEM with 5 µg/mL Polybrane, and incubated
overnight. After 24 hours, the media solution containing Polybrane was aspirated and
replaced with 10% FBS DMEM.

2.1.3 Cell Maintenance
Upon reaching 100% confluency, the cells were split. The cells were washed with
PBS, 1 mL of 0.5% trypsin was added, and then incubated for 5-15 minutes for
detachment. To ensure proper detachment from the plate, the detachment of cells after
administration of trypsin were confirmed with the microscope. After splitting, the cells
were incubated to allow for healthy expansion.
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2.1.4 Cell Stock Preparation
Storage of cell lines for long-term use was prepared by making cell stock solutions
in cryovials. 10 mL of media was added by jet flow to each 10 cm plate of cells after
trypsinization.

The cell-media solution was collected, placed in a 25 mL vial, and

centrifuged at 800 rpm for 5 minutes. After centrifugation, the media supernatant was
removed by aspiration, leaving the cell pellet intact. The pellet was lightly tapped and
about 3 mL of Bambanker serum-free cell freezing medium (Lymphotec Incorporated,
Tokyo, Japan) was added to the pellet in a suspension. Per 3 mL suspension of trypsinized
cells and Bambanker solution, 4-5 cryovials were generated. All cryovials were placed in
a -80°C freezer for later use.

2.2 Reagents and Antibodies
Human recombinant erythropoietin alfa (EPOGEN®) was purchased as a 4,000
U/mL vial and stored at 4 °C until further use (Amgen Incorporated, Thousand Oaks, CA).
An antibody specific for EPO (R&D Systems, Minneapolis, MN) was purchased for
proliferation experiments.

Monoclonal antibodies for total α-tubulin (Cell Signaling

Technology Incorporated, Danvers, MA, Cat. Number: SC-2125, Lot 11H10, Anti-Rabbit),
Akt (Cell Signaling Technology Incorporated, Danvers, MA, Cat Number: 9272, Lot 18,
Anti-Rabbit), ERK 1/2 (Santa Cruz Biotechnology Incorporated, Santa Cruz, CA, Cat.
Number: (c-16): sc-93, Anti-Rabbit), JNK (Santa Cruz Biotechnology Incorporated, Santa
Cruz, CA, Cat. Number: sc-571, Lot K140, Anti-Rabbit), and STAT5 (Cell Signaling
Technology Incorporated, Danvers, MA, Cat. Number: 9358, Lot 2, Anti-Rabbit) were
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purchased for western blot signaling experiments.

Monoclonal antibodies for

phosphospecific p-Akt (Ser473) (Catalog Number: 9271S; Cell Signaling Technology
Incorporated, Danvers, MA, Lot 11, Anti-Rabbit), p-ERK 1/2 (Cell Signaling Technology
Incorporated, Danvers, MA, Cat. Number: 4695, Lot 5, Anti-Rabbit), p-JNK
(Thr183/Tyr185) (Cell Signaling Technology Incorporated, Danvers, MA, Cat. Number:
9255S, Lot 15, Anti-Mouse), and p-STAT5 (Tyr 694) (Cell Signaling Technology
Incorporated, Danvers, MA, Catalog Number: 9359S, Lot 4, Anti-Rabbit) were purchased.
FITC conjugated IgG antibody (Catalog Number: 4030-05, Lot B3509-N250E, AntiRabbit) was purchased for secondary antibody detection.

2.3 RNA Extraction
RNA was extracted from 60 mm2 cell culture plates at 60% confluency using an
RNeasy Mini Kit with RNeasy spin columns, QIAGEN® Shredder, and RNase-Free DNase
Set according to protocol provided by the manufacturer (QIAGEN® Incorporated,
Valencia, CA). The RNA generated was stored at -80°C until further use. RNA purity
was evaluated using the NanoDrop ND-1000 spectrophotometer with 1 µL of each RNA
sample (Thermo Fisher Scientific, Waltham, MA).

2.4 Reverse Transcription
Complementary DNA (cDNA) was generated using the High Capacity cDNA
Reverse Transcription achieve kit (Applied Biosystems, Foster City, CA). 1 µg of RNA
was reverse-transcribed with a total volume of 20µL of 2X RT Master Mix (10x reverse
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transcriptase buffer, 25x deoxyribonucleotide triphosphate mix, 10x RT random primer,
MultiScribeTM reverse transcriptase, RNase inhibitor, and nuclease-free water) to generate
cDNA. The reaction was conducted in a thermal cycler as a four-step reaction: (1) 10
minutes at 25°C, (2) 120 minutes at 37°C, (3) 5 minutes at 85°C, and (4) infinite minutes at
4°C. cDNA synthesized was stored at -20°C until needed for further use.

2.5 Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR)
Quantitative real-time polymerase chain reaction (qRT-PCR) is a quantification
method that exponentially amplifies and quantifies short sequences within longer
sequences of a targeted DNA molecule. qRT-PCR provides a unique perspective of a
gene’s function and regulation by quantification of its messenger RNA (mRNA) levels.
To properly quantify mRNA, cDNA is first generated by an RNA-dependent DNA
polymerase enzyme called reverse transcriptase, as described under ‘Reverse
Transcription’. The reverse transcribed cDNA lacks introns, or non-coding nucleotide
sequences that are removed by RNA splicing. Generation of cDNA is therefore useful for
reproducing eukaryotic genomes excluding large non-coding segments, and is a reliable
method to quantify genes expressed in an organism.
The sequence amplification process of qRT-PCR occurs in real time as the DNA is
detected. The cDNA is amplified, which employs the use of primer sequences that are
complementary to the two strands of DNA. The complete reaction takes place in a thermal
cycler, where various series of temperature settings are applied for template denaturation,
primer annealing, and primer extension.
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After the reaction concludes, absolute

quantification of mRNA levels is evaluated to detect gene expression levels in the desired
cell types.
qRT-PCR (Taqman® qRT-PCR) was performed using primers to both the
housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), and an EPOR
transcript region. GAPDH was used as a positive homogenous control against EPOR to
compare background levels of cDNA.

Taqman® Gene Expression Assay primer

HS00959427_m1 for EPOR and Taqman® 20x GAPDH primer probe dye: FAM-MGB
were used (Applied Biosystems, Foster City, CA).
The quantitative real-time PCR reaction was performed in triplicate in a total
volume of 20 µL in a 96-well optical reaction plate [5 µL cDNA, 10 µL Taqman® 2x
Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 1 µL 20x primer, 4 µL
distilled water]. GAPDH primers were diluted in a 1:10 ratio. The plate was covered with
an optical cover to prevent leakage before being placed into the amplification machine.
cDNA was amplified with 7500 HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) through the following reaction steps: (1) activation for 2
minutes at 50°C, (2) denaturation for 20 seconds at 95°C, (3) 40 cycles of melting for 3
seconds at 95°C and annealing/extending for 30 seconds at 60°C, respectively.

The

average ∆∆CT values were calculated and ∆RQ, or relative quantification was measured
using SDS 2.2 software. The difference in ∆RQ values was calculated and analyzed based
on GAPDH expression levels.
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2.6 Cell Proliferation Assay
HN4 and HN12 cells were seeded in triplicate at a cell density of 5 x 103 and
2 x 103 cells, respectively, in 24-well tissue culture plates. To prepare the experiment,
cells were washed with PBS, and cultured in DMEM and 10% FBS (supplemented with
streptomycin, penicillin, and puromycin). In those experiments conducted to determine
cell responsiveness to EPO, a concentration varying from a range of 0 U/mL to 10 U/mL
of EPOGEN® was applied as shown in Results when cells were seeded.

This cell

preparation was then placed in a 37°C, 90% air, and 10% CO2 incubator for a two day
period. After the two day growth period, the first triplicate was washed twice with 1 mL of
PBS.

The PBS solution was aspirated, and 200 µL of trypsin was applied to each

individual well of the triplicate. The 24-well plate was placed in the 37°C, 90% air, and
10% CO2 incubator for 20 minutes to allow for complete cell detachment. After cell
detachment, all cells were resuspended and placed into separate eppendorf tubes. 20 µL of
each resuspended cell solution was placed into the Improved Neubauer Haemocytometer
chamber to be counted.
The total amount of cells was counted in the four exterior boxes located in the
corners of the nine box grid (as shown in Figure 10). The total number of cells was
divided by four to obtain an average number of cells per well. This was repeated for all
three samples for each cell line. Preparation of the cells and the counting steps were
repeated for the second triplicate of cells on day 2 of the experiment, and the same for each
successive day. After a six day counting period was completed, a cell proliferation curve
was generated.
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Figure 10.

Hemocytometer Counting Method for Proliferation Assay. Cells

were counted in the four exterior boxes designated by arrows of the
hemocytometer field.

2.7 Cell Scratch Assay
A cell scratch assay is an effective method to evaluate in vitro cell migration. A
scratch is applied in a cell monolayer, and images of the scratch closure are taken at time
intervals appropriate to the cell line to quantify migration. The scratch assay emulates cell
migration in vivo during wound healing, and mimics cell to cell interactions. HN4 and
HN12 cells were seeded in triplicate at a cell density of 2.5 x 105 cells in 24-well tissue
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culture plates. Cells were washed with PBS, and cultured in DMEM and 10% FBS
(supplemented with streptomycin, penicillin, and puromycin) for 24 hours. For EPO
specific experiments, a final concentration of 10 U/mL EPOGEN® was applied to the first
triplicate of each cell line at the time of seeding, and the second triplicate served as a
negative control with no application of EPOGEN®.
A single scratch using a sterile P200 pipette tip was administered with equal
pressure throughout from the top to the bottom of each well in the 24-well plate. The
scratch distance was measured at ‘time 0’ (0 hours) and an image of the distance was taken
in two areas of each scratch using ZEISS® Axiovert 200M microscope with AxioVision®
digital image processing for widefield microscopy. Cells were incubated and allowed to
grow towards the center of the plate for 8 hours for HN12 BG and HN12 EPOR 16 cell
lines, and 12 hours for HN4 BG and HN4 EPOR 16 cell lines.
The distance of scratch closure was measured at 8 hours and 10 hours for all HN12
and HN4 cell lines, respectively. An image at these times was taken to show migration
rate compared to distance measured at 0 hours in the same location. Scratch closure
distances in both cell lines were compared between those cells applied with EPOGEN® and
the control, and calculated as a retardation ratio according to the following formula:

(Scratch Width at 0 hours) - (Scratch Width at 8 or 12 hours) x 100
Scratch Width at 0 hours

The scratch assay was repeated for a total of three separate experiments and
retardation ratios were consolidated as an average.
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An HN4 and HN12 cell scratch assay in response to EPO was completed under
control conditions (0 U/mL EPOGEN®), or in 10 U/mL EPOGEN® conditions. A cell
retardation ratio was calculated based on the difference in migration between EPO+ and
EPO- cells according to the following formula:

EPO+ Distance of Scratch Closure x 100
EPO- Distance of Scratch Closure

This ratio was compared to 1 (no difference in retardation between EPO+ and EPO-).

2.8 Western Blot

2.8.1 Collection of Cell Lysate
A mitogen-associated protein kinase (MAPK) 1x lysis buffer solution for
MAPK/JNK/p38 was prepared by adding 50 µL 1 M DTT, 100 µL 1 M sodium
orthovanadate, 500 µL 0.1 M PMSF, and 50 µL protease inhibitor per 50 mL lysis buffer
solution. The solution was then centrifuged for one minute at maximum speed. HN4 and
HN12 cells were cultured in a 37°C humidified incubator, with 90% air and 10% CO2.
After reaching 60% confluency, the medium was decanted, and the cells were washed with
cold PBS twice. The culture plates were stored at a -80°C location until used. 300 µL of
the MAPK lysis buffer was added drop-wise to cover all areas of each thawed cell plate for
15 minutes. After 15 minutes, the cell lysates were gathered, placed in eppendorf tubes,
and centrifuged at 16,000 x g for 15 minutes at 4°C. The supernatant was extracted after
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centrifugation and placed in new eppendorf tubes. The cell lysates were storaged at -80°C
until further usage.

2.8.2 Standard Curve Generation
A standard curve was generated using a Bradford assay with appropriate amounts
of Bovine Serum Albumin (BSA), water, and Bio-RAD (BioRad Laboratories, Hercules,
CA) at a 1:5 dilution with a spectrophotometer at a wavelength of 595 nm. A blank
measurement of absorbance was made first, then five standard measurements. Protein
concentration measurements of samples were calculated according to absorbances
measured by spectrophotometer. Well loading amounts were calculated based on the
concentration of the thinnest protein. A total amount of 30 µL was made of sample
amount, lysis buffer, and loading buffer.

2.8.3 Preparation of Gel
Two clean glass plates were securely clamped in a casting frame for each gel
prepared. 12% resolving gel mix was prepared in the following amounts: 3.3 mL distilled
de-ionized water, 2.5 mL gel buffer (1.5 M Tris-HCl at pH 8.8), 0.1 mL 10% SDS, 4.0 mL
30% Acrylamide Bis. Stacking gel mix was prepared in the following amounts: 1.4 mL
distilled de-ionized water, 0.25 mL gel buffer (1.0 M Tris-HCl at pH 6.8), 0.02 mL 10%
SDS, 0.33 mL 30% Acrylamide Bis. 100 µL 10% ammonium persulfate (APS) was added
to the resolving gel mix and inverted. 4 µL tetramethylethylenediamine (TEMED) was
added to the resolving gel mix and inverted. The resolving gel mix was added up to a 1 cm
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margin from the top of the plates. The resolving gel was allowed to harden for a minimum
of 30 minutes and residual water was discarded. 20 µL 10% APS and 2 µL TEMED were
added to the stacking gel mix and inverted. The stacking gel was quickly loaded just
above the height of the short plate. The well teeth were inserted into the top of the
stacking gel and allowed to harden for a minimum of 30 minutes. If not for immediate use,
the gel was wrapped and placed in a -20° location until needed for further use.

2.8.4 Gel Electrophoresis
5 µL loading buffer was added to protein and lysis buffer amounts calculated
earlier. Each protein-buffer solution was heated between 95-100°C for 5 minutes and
centrifuged at maximum speed. The prepared gel was placed into a gel cassette sandwich
for electrode assembly. 1x running buffer was poured into the gel cassette sandwich
between and on the outside of the glass plates. 3 µL gel marker was added to the first well.
25 µL of each sample was then loaded to each respective well. The cassette lid was
replaced, electrode colors were matched, and the gel was set to run at 125 V, 400 mA for 1
hour and 30 minutes.

2.8.5 Gel Transfer to Membrane
After gel electrophoresis was completed, the running buffer was discarded. The gel
plates were pried open and the stacking gel was trimmed off. The resolving gel was pried
off the glass and soaked in 1x transfer buffer. Two fiber pads, fiber paper, and the
membrane were soaked in the transfer buffer before being added into a sandwich for
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electrode assembly. One fiber pad and paper were laid down onto the gel cassette. The gel
was then placed onto the paper, and a polyvinylidene difluoride membrane (BioRad
Laboratories, Hercules, CA) was directly placed on the gel after being soaked in 100%
methanol and transfer buffer. The second fiber paper and pad were placed on top of the
membrane to complete the sandwich.
The gel cassette holder was securely closed, and placed into the electrode module
in the buffer tank. The transfer buffer was placed into the buffer tank, leaving room for an
ice block. The ice block was placed in the buffer tank and additional transfer buffer was
placed into the buffer tank. The lid was replaced and the electrode colors were matched.
The transfer assembly was set for overnight run at a continuous 8 mA.

2.8.6 Blotting the Membrane
After gel transfer, the gel and membrane were removed from the cassette. The gel
was discarded. 2.5 g of dry milk was dissolved in 50 mL of 1x Tris-Buffered Saline and
Tween-20 (TBST). The membrane was placed into a seal pak with the 5% TBST/milk
solution, sealed, and blocked with gentle agitation for 30 minutes. After the blocking step,
the membrane was washed three times for 5 minutes each. The necessary amount of
primary antibody was diluted in 1% BSA or 5% TBST/milk solution to generate a 1:1000
dilution.

The membrane was placed into a new seal pak and the primary

antibody/TBST/milk solution was added into the pak, and sealed (ensuring all bubbles
were squeezed out). The membrane was incubated overnight on a rocker in a 4°C cold
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room. The solution was discarded and the membrane was washed in 1x TBST solution in
a small dish for 2 cycles of 10 minutes, and 1 cycle of 30 minutes.
The necessary amount of secondary antibody was added to TBST/milk solution to
generate a 1:10,000 dilution. The membrane was placed into a new seal pak and the
secondary antibody/TBST/milk solution was added into the pak, and sealed (ensuring all
bubbles were squeezed out). The membrane was incubated for 1 hour at room temperature
with gentle agitation. The solution was discarded and the membrane was washed in 1x
TBST solution for 2 cycles of 10 minutes, and 1 cycle of 30 minutes.

2.8.7 Exposure of Membrane to Film
The membrane was placed on top of pre-placed saran wrap on the bottom of an
autoradio cassette. 500 µL of enhancer solution and 500 µL of peroxide buffer using a
Western Lightning Chemiluminescence Plus system was used for protein detection. The
solution was thoroughly mixed and distributed evenly on top of the membrane to all
surfaces. The solution was allowed to sit for 5 minutes. Any residual solution was then
discarded. The membrane was wrapped in saran wrap and the cassette was closed. In a
dark room, the cassette was opened and the membrane was placed in the corner of the
cassette. Blue Devil autoradiography film (Genesee Scientific, San Diego, CA) was placed
directly on top of the membrane and the cassette was closed for the desired amount of
time. The film was placed into a Kodak photo-processing developer machine for exposure.
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2.9 Statistical Analysis
Two-group comparisons were performed by using paired student t-test analysis
with Excel and GraphPad software (GraphPad Software, Inc, La Jolla, CA). A two-tailed
P value of P < 0.05 was considered to be statistically significant.

51

Results

3.1 Knockdown of EPOR Expression
To investigate the biological role of EPO/EPOR in HNSCC, mRNA expression of
EPOR was first examined. The HN12 cell line, derived from a lymph node metastasis in a
patient with HNSCC, was previously found to possess more than twice greater EPOR
expression compared to HN4 as shown in Figure 11 in an experiment prior to this study.
High EPOR expression in the breast cancer MCF-7 cell line is also shown, similar to
HN12. HN4 is a cell line derived from the same patient as the HN12 cell line, but from a
primary lesion of the cancer. These differing results in EPOR expression in HN4 and
HN12, therefore suggested that both cell lines could possibly produce a varying response
to EPO. To determine the impact of EPOR on survival, proliferation, and migration of
HN4 and HN12 cells, lentiviral vector-mediated RNA interference was used to inhibit the
expression of EPOR. HN4 and HN12 cells were stably infected with a lentivirus vector
that synthesizes shRNA targeted to degrade EPOR mRNA.

A non-targeting control

plasmid was used a tool for comparison to the shRNA EPOR infections. HN4 and HN12
NTC and EPOR shRNA clones (HN12 shR16, HN12 shR14) were selected for resistance
to puromycin, RNA was extracted, reverse transcribed, and qRT-PCR was performed.
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HN12 shR16 EPOR expression was downregulated more than 60% when compared
to HN12 NTC with qRT-PCR, as shown in Figure 12. This downregulation was found to
be statistically significant, with a p-value less than 0.0001.

HN12 shR14 was also

downregulated more than 20% when compared to HN12 NTC. This downregulation was
found to be statistically significant, with a p-value less than 0.01. From these results,
successful knockdown of EPOR expression was therefore achieved in HN12 cells.
HN4 shR16 EPOR expression was downregulated more than 30% when compared
to HN4 NTC as shown in Figure 13. This value was found to be statistically significant,
with a p-value less than 0.01.

HN4 shR14 EPOR expression was not found to be

significant, and thus HN4 shR16 was chosen to be a more successful knockdown candidate
for comparison to HN12 in further experiments. HN4 and HN12 cells were used in
parallel as a comparison tool in all further experimentation due to their differing abilities to
express EPOR.

EPOR Expression
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Figure 11.

EPOR expression levels were previously screened by qRT-PCR in several

HNSCC cell lines, as well as the MCF-7 breast cancer cell line as a reference, a cancer
form studied extensively in EPO treatment.
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HN12 EPOR Expression
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Figure 12.

HN12 shR16

HN12 shR14

RNA was isolated from subconfluent cultures of HN12 cells, reverse

transcribed, and qRT-PCR was performed as described in Materials and Methods. The
expression of EPOR was standardized to the homogenous control, GAPDH. The qRTPCR experiment was performed in triplicate and relative means ± SEM are shown. A
statistically significant decrease in EPOR expression levels was found in HN12 shR16 and
HN12 shR14 infected cells compared to the HN12 vector control (**** represents
p<0.0001, and ** represents p<0.01).
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HN4 EPOR Expression

Relative Expression (arbitrary units)
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Figure 13.

HN4 shR16

HN4 shR14

RNA was isolated from subconfluent cultures of HN4 cells, reverse

transcribed, and qRT-PCR was performed as described in Materials and Methods. The
expression of EPOR was standardized to the homogenous control, GAPDH. The qRTPCR experiment was performed in triplicate and relative means ± SEM are shown. A
statistically significant decrease in EPOR expression levels was found in HN4 shR16
infected cells compared to the HN4 vector control (** represents p<0.01).
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3.2 Downregulation of EPOR Leads to Decreased Cell Proliferation
Cellular growth and proliferation in cancer promotes tumorigenesis and metastasis
of the disease. It was, therefore, imperative to observe how HNSCC proliferates in both
the primary lesion cell line, HN4, and the metastatic cell line, HN12. Also important to
understand was the role EPOR plays in proliferation of these cells. Thus, the HN12 shR14
and shR16 constructs were used as they were found to stably express EPOR
downregulation in HN12. HN12 NTC cells were used as a means for comparison against
the knockdown cells. The shR16 construct of HN4 was used along with HN4 NTC to
compare with HN12 proliferation. 2x103 and 5x103 HN12 and HN4 cells, respectfully, per
well in serum conditions were plated in triplicate in 24-well culture plates, and cultured for
2 days to allow initial growth. A greater cell amount was seeded for HN4 based on its
general growth potential, which grows at a slower rate than metastatic HN12 cells. Cell
counting was performed for the following 6 days after trypsinization as described in
Materials and Methods, and proliferation was compared between the control groups and
the shEPOR groups.

As shown in Figure 14, a 50% decrease in average HN12

proliferation was observed in both EPOR knockdown constructs (HN12 shR16 and HN12
shR14) when compared to HN12 control. This decrease was found to be statistically
significant, with a p-value less than 0.001 at day 6.
Similarly, average HN4 proliferation was decreased almost 50% in HN4 shR16
when compared to HN4 control, as shown in Figure 15. This was also found to be a
statistically significant decrease, with a p-value less than 0.001 at day 6. Overall, cell
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proliferation was suppressed in HN4 and HN12 EPOR knockdown cells when compared to
their non-targeting controls.
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HN12 Cell Proliferation
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Figure 14.

HN12 cells were seeded in triplicate at a density of 2 x 103 and were

counted for six consecutive days following a two-day growth period. An average number
of cells were calculated each day, and the means ± SEM are shown. A statistically
significant downregulation in proliferation was found in HN12 shR16 and HN12 shR14
infected cells compared to the HN12 vector control (*** represents p<0.001).
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HN4 Cell Proliferation
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Figure 15.

HN4 cells were seeded in triplicate at a density of 5 x 103 and were counted

for six consecutive days following a two-day growth period. An average number of cells
were calculated each day, and the means ± SEM are shown. A statistically significant
downregulation in proliferation was found in HN4 shR16 infected cells compared to the
HN12 vector control (*** represents p<0.001, and * represents p<0.05).
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3.3 Erythropoietin Suppresses HN12 Proliferation
In order to study the role of EPO in conjunction with EPOR in cell proliferation,
increasing concentrations of EPOGEN® were administered to HN12 NTC cells in serum
conditions to observe how EPO impacts growth of the metastatic cell line. A concentration
of 0 U/mL EPO was termed the control, and doses were increased in a range up to 10
U/mL EPO as the maximum concentration. 10 U/mL EPO was selected as the maximum
concentration to be applied to the HN12 cells, as it was reported to be adequate to elicit
cellular responses in previous studies conducted in other cancers(13,41,49). 2x103 HN12
NTC cells per well were plated in triplicate with either 0 U/mL, 0.25 U/mL, 1 U/mL, 5
U/mL, or 10 U/mL EPO, cultured for 2 days, and counted for 6 days as performed
previously. A dose-response curve was established as shown in Figure 16 with each
respective EPO concentration over the 6 day period. HN12 proliferation was suppressed in
response to increasing concentrations of EPO when compared to the control (no EPO
application).

A 40% suppression of proliferation was observed in 1 U/mL EPO

concentration, a 48% suppression in 5 U/mL EPO, and a 50% suppression in the 10 U/mL
EPO concentration. The decreases in proliferation produced by 1 U/mL-10 U/mL EPO
conditions were found to be statistically significant at day 6 when compared to control
conditions with no EPO (p-value less than 0.05 for 1 U/mL and 5 U/mL; p-value less than
0.01 for 10 U/mL). This proliferation assay showed us that EPO effectively produces a
suppression of HN12 proliferation at a minimum concentration of 1 U/mL. 1 U/mL EPO
could therefore be used to observe downregulation in further proliferation studies.

60

HN12 Cell Proliferation in Response to Erythropoietin (EPO)
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Figure 16.

HN12 NTC cells were seeded under conditions of 0 U/mL to 10 U/mL

EPOGEN® in triplicate at a density of 2 x 103 and were counted for six consecutive days
following a two-day growth period. An average number of cells were calculated each day,
and the means ± SEM are shown as a dose-response relationship. A concentration of
1 U/mL-10 U/mL was found to suppress HN12 proliferation. A statistically significant
difference was observed at day 6 with conditions of 1 U/mL-10 U/mL EPO (p<0.05 for 1
U/Ml and 5 U/mL; p<0.01 for 10 U/mL).
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3.4 EPO-Specific Antibody Restores HN12 Proliferation
To fully determine whether addition of exogenous EPO to HN12 NTC cells was
suppressing their proliferation, a neutralizing antibody specific for EPO was applied to the
cells in serum conditions with and without EPO independently in a follow-up experiment.
An IgG antibody was used as a control for application of the EPO antibody. HN12 NTC
cells with no application of antibodies or EPOGEN® was used as a control for all other
conditions: HN12 NTC with IgG, HN12 NTC with EPO antibody, HN12 NTC with 1
U/mL EPOGEN® and IgG, and HN12 NTC with 1 U/mL EPOGEN® and EPO antibody.
2x103 HN12 cells per well were plated in triplicate in each of these five conditions,
cultured, and counted for 6 days in the previously established manner. Application of IgG
to the HN12 cells produced a proliferation response similar to the HN12 control cells, as
shown in Figure 17. Application of the EPO-specific antibody also did not produce a
noticeable difference when compared to the control group.

Application of 1 U/mL

EPOGEN® in the presence of IgG, however, decreased proliferation almost 50%, similar
to the trend previously seen in Figure 16. This decrease confirms the potential for EPO to
suppress HN12 proliferation, and also establishes IgG as an effective control against the
EPO antibody.

Application of 1 U/mL EPO in the presence of the EPO antibody

impressively restored 50% of the suppressed HN12 proliferation back towards normal
levels seen in the control group.

These results confirmed that addition of EPO is

responsible for suppression of HN12 proliferation. Successful restoration of proliferation
by the EPO antibody also showed high specificity.
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HN12 Cell Proliferation in Response to EPO-Specific Antibody
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Figure 17.

HN12 cells were seeded under control conditions (0 U/mL EPOGEN®) or

1 U/mL EPOGEN® in triplicate at a density of 2 x 103 and were counted for six
consecutive days following a two-day growth period. Application of an IgG-specific
antibody or EPO-specific antibody was performed under control conditions and under
conditions of 1 U/mL EPOGEN®. An average number of cells were calculated each day,
and the means ± SEM are shown. A statistically significant difference was observed at day
6 with conditions of 1 U/mL EPOGEN® + IgG (p<0.05).
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3.5 MCF-7 Cells Possess a Differential Response to EPO
Several studies performed in MCF-7 breast cancer cells report an increase in
proliferation rates when exposed to exogenous EPO treatment(13,41). Combined with these
findings and high expression of EPOR (similar to HN12) as shown in Figure 11, MCF-7 is
an ideal cell line to compare proliferation between HNSCC and other cancer forms in
response to EPO.

A preliminary experiment conducted with 1 U/mL EPOGEN®

application to MCF-7 cells did not produce a noticeable change in proliferation.
Therefore, a higher concentration of 10 U/mL EPOGEN® was applied to observe a
biological response in MCF-7 cells. 10 U/mL EPO is also the optimal concentration
established by the previous breast cancer studies mentioned above to produce an increase
in proliferation in MCF-7 cells specifically. 2x103 HN12 and MCF-7 cells per well were
plated in triplicate under (1) control conditions, (2) with addition of 1 U/mL EPOGEN®,
(3) with addition of 10 U/mL EPOGEN®, cultured, and counted for 6 days in the
previously established manner. EPO application in conditions of 1 U/mL and 10 U/mL
decreased HN12 proliferation with increasing concentration, as seen previously in Figure
16. MCF-7 proliferation, however, was increased in response to EPO at a concentration of
10 U/mL (Figure 18), consistent with studies conducted in the same cell line(13,41). As
concluded by the test experiment mentioned, MCF-7 cells exposed to 1 U/mL EPO did not
show a difference from the MCF-7 control cells without application of EPO, as can be seen
in Figure 18. These results obtained from HN12 and MCF-7 proliferation conducted side
by side show opposing responses to exogenous EPO.
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HN12 and MCF-7 Cell Proliferation in Response to EPO
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Figure 18.

HN12 cells and MCF-7 breast cancer cells were seeded under control

conditions (0 U/mL EPOGEN®), 1 U/mL EPOGEN®, and 10 U/mL EPOGEN® in
triplicate at a density of 2 x 103 and were counted for six consecutive days following a
two-day growth period. An average number of cells were calculated each day, and the
means ± SEM are shown. A statistically significant decrease in proliferation was observed
at day 6 in HN12 cells supplemented with 10 U/mL EPOGEN® compared to control
conditions (p<0.01). A statistically significant increase in proliferation was observed in
MCF-7 cells supplemented with 10 U/mL EPOGEN® (p<0.05).
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3.6 Unaffected Migration of HN4 and HN12 in Response to EPO
In addition to an effect on proliferation, EPO may promote cellular motility in HNSCC.
Migration of these cells in vitro can indicate how they metastasize from their primary
tumor location into other tissues. To observe migration, a scratch assay was performed in
both HN4 and HN12 NTC cells and their EPOR knockdown constructs (HN4/HN12
shR14, shR16). All cell lines were seeded in triplicate at a density of 2.5 x 105 and grown
to 100% confluency. A scratch was performed as described in Materials and Methods and
incubated for 8 hours in all HN12 cells, and 10 hours in all HN4 cells to allow for cell
migration. The distance migrated was calculated using AxioVision® software at the end of
these time durations in two specific places (noted in Figure 21). No statistically significant
difference in migration was observed in HN12 or HN4 EPOR knockdown constructs when
compared to their control cell lines (Figures 19 and 20), with p-values greater than 0.05.
All HN4 and HN12 cells were then tested for migratory response to EPO with the same
scratch assay procedure. Maximum concentration of 10 U/mL EPOGEN® was applied to
achieve a response in migration in the same cell lines. EPO(-) conditions were established
with no application of EPO to serve as a control for EPO(+) cells. Distances migrated
were calculated using AxioVisionfor both conditions to determine differences with and
without application of EPOGEN®. No significant difference in migration was observed
between EPO(+) and EPO(-) conditions in both HN4 and HN12 control and knockdown
constructs, with p-values greater than 0.05 (Figures 22 and 23). These results show no
differences in migration between HN4 and HN12 control and EPOR knockdown cells, as
well as no significant effect of EPO.
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HN12 Cell Scratch Assay
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Figure 19.

HN12 shR14

HN12 shR16

HN12 cells were seeded at a density of 2.5 x 105 and grown to confluency

in triplicate. Upon reaching confluency, a scratch assay was completed in triplicate as
described in Materials and Methods. A cell retardation ratio was calculated based on the
migration distance at 8 hours as described in Materials and Methods. An average of these
ratios was calculated and is shown ± SEM (p=0.3244 for HN12 shR14, and p=0.4392 for
HN12 shR16 compared to NTC).

These results are representative of three separate

experiments conducted.
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HN4 Cell Scratch Assay
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Figure 20.
triplicate.

HN4 shR14

HN4 shR16

HN4 cells were seeded at a density of 2.5 x 105 and grown to confluency in
Upon reaching confluency, a scratch assay was completed in triplicate as

described in Materials and Methods. A cell retardation ratio was calculated based on the
migration distance at 10 hours as described in Materials and Methods. An average of these
ratios was calculated and is shown ± SEM (p=0.2323 for HN4 shR14, and p=0.2811 for
HN4 shR16 compared to NTC).

These results are representative of three separate

experiments conducted.
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Figure 21.

HN12 at 0 hours

HN12 at 8 hours

HN4 at 0 hours

HN4 at 10 hours

HN4 and HN12 cells were seeded at a density of 2.5 x 105 and a scratch was

performed at 0 hours. The distance migrated was measured using ZEISS® Axiovert 200M
microscope with AxioVision® digital imaging software after 10 hours of growth for HN4
cells, and 8 hours of growth for HN12 cells. Representative AxioVision® images of the
cells are shown at 0 and 8 or 10 hours.
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HN12 Cell Scratch Assay in Response to Erythropoietin (EPO)
2
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Figure 22.

HN12 shR16

HN12 shR14

HN12 cells were seeded at a density of 2.5 x 105 and grown to confluency

under conditions of 10 U/mL EPOGEN® in triplicate or control conditions (0 U/mL). A
scratch assay was completed as described in Materials and Methods. A cell retardation
ratio was calculated based on the difference in migration between EPO(+) and EPO(-) cells
as displayed in Materials and Methods. This ratio was compared to 1 (no difference in
retardation between EPO(+) and EPO(-). An average of these ratios was calculated and is
shown ± SEM (p=0.9462 for HN12 shR14, and p=0.8448 for HN12 shR16 compared to
NTC). These results are representative of three separate experiments conducted.
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HN4 Cell Scratch Assay in Response to Erythropoietin (EPO)
2
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Figure 23.

HN4 shR16

HN4 shR14

HN4 cells were seeded at a density of 2.5 x 105 and grown to confluency

under conditions of 10 U/mL EPOGEN® in triplicate or control conditions (0 U/mL). A
scratch assay was completed as described in Materials and Methods. A cell retardation
ratio was calculated based on the difference in migration between EPO(+) and EPO(-) cells
as displayed in Materials and Methods. This ratio was compared to 1 (no difference in
retardation between EPO+ and EPO-). An average of these ratios was calculated and is
shown ± SEM (p=0.7705 for HN12 shR14, and p=0.6584 for HN12 shR16 compared to
NTC). These results are representative of three separate experiments conducted.
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Figure 24.

HN12 at 0 hours
EPO(+)

HN12 at 8 hours
EPO(+)

HN12 at 0 hours
EPO(-)

HN12 at 8 hours
EPO(-)

HN4 and HN12 cells were seeded at a density of 2.5 x 105 and grown to

confluency in control conditions (0 U/mL) or under conditions of 10 U/mL EPOGEN® in
triplicate. A scratch was performed at 0 hours. The distance migrated was measured using
ZEISS® Axiovert 200M microscope with AxioVision® digital imaging software after 10
hours of growth for HN4 cells, and 8 hours of growth for HN12 cells. Representative
AxioVision® images of the cells are shown at 0 and 8 hours for HN12 cells.
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3.7 Activation of Pro-Survival Signaling Pathways
Molecular pathways leading to survival, proliferation, and migration of cells in cancer
contribute to tumor metastasis, including in HNSCC. The EPO/EPOR mechanism, in
particular, can promote such pathways to be activated. This activation is contingent upon
the ability of specific molecules to phosphorylate downstream effector molecules involved
in these signal transduction events. It was crucial, therefore, to test the kinase activity of
molecules reported to be activated by EPO/EPOR, including ERK 1/2, Akt, and STAT5 by
western blot analysis.

HN4 and HN12 cells were lysed, electrophoresed, proteins

transferred to a membrane, and detected with appropriate antibodies. Antibodies against
total content of these molecules were first applied to ensure even protein concentration and
proper loading. Phospho-specific antibodies were then applied against the same molecules
to determine ability to phosphorylate as described in Materials and Methods. Anti-αtubulin was used as an additional loading control. Results from these detections exhibit
greater activation of p-Akt in HN12 cells compared to HN4 cells as shown in Figure 25.
Densitometric analysis conducted with Image J software showed p-Akt in HN12 control
expression to be 3.83 times greater than total Akt content.

p-Akt in HN12 shR14

expression was found to be 2.61 times greater than total content, and p-Akt in HN12 shR16
expression was 2.82 times greater than total Akt. In comparison, p-Akt in HN4 expression
was about 0.5 times the expression of total Akt content in all cell lines tested. p-JNK and
p-STAT5 images were not successfully generated, and these signals were concluded too
weak to be considered in these cells.
HN12 NTC and MCF-7 cells were then cultured with 10 U/mL EPOGEN®
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(0 U/mL EPO served as control) for two days to determine possible effect of EPO on
kinase activity of the same molecules, as shown above. Cells were lysed, proteins run and
transferred, and membranes probed in an identical manner. p-Akt activity in MCF-7 cells
exposed to EPO shows a slight upregulation when compared to the cells in control
conditions as shown in Figure 26. Densitometric analysis showed p-AKT in MCF-7 to be
2.42 times the expression of total Akt in 10 U/mL EPO conditions, whereas p-Akt in MCF7 in 0 U/mL EPO conditions was only 0.51 times the expression of total Akt. p-ERK
activity in MCF-7 also showed a slight upregulation when compared to control conditions.
Densitometric analysis showed p-ERK in MCF-7 to be 1.11 times the expression of total
content of ERK in 10 U/mL EPO conditions, whereas p-ERK in MCF-7 in 0 U/mL EPO
conditions was only 0.84 times the expression of total ERK. p-ERK activity in HN12
showed a slight downregulation in 10 U/mL EPO conditions when compared to control
conditions. Densitometric anaylsis showed p-ERK in HN12 control to be 0.87 times the
expression of total ERK in 10 U/mL conditions, whereas p-ERK in HN12 in 0 U/mL EPO
conditions was 1.13 times the expression of total ERK. p-JNK and p-STAT5 images were
not successfully generated in these conditions, similarly to Figure 25.
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HN12 shR16

HN12 shR14

HN12 Control

HN4 shR16

HN4 shR14

HN4 Control
60kDa

AKT

60kDa

p -AKT

44kDa

ERK

44kDa

p -ERK
Tubulin

50kDa

Figure 25.

HN4 and HN12 cells were lysed, gel electrophoresis performed, proteins

transferred to a membrane, and specific antibodies applied to the membrane to test total
molecule content and kinase activity as described in Materials and Methods. Even
concentration and equal loading was shown with tubulin and total molecule content.
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Figure 26.

MCF-7

HN4 and HN12 cells were cultured for two days in conditions of 0 U/mL

EPOGEN® or 10 U/mL EPOGEN®. Cells were lysed, gel electrophoresis performed,
proteins transferred to a membrane, and specific antibodies applied to the membrane to test
total molecule content and kinase activity as described in Materials and Methods. Even
concentration and equal loading was shown with tubulin and total molecule content.
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Discussion

4.1 Current Study
The aim of the current study was to determine the role of the ligand, EPO, and its
receptor, EPOR, in proliferation, survival, and motility of HN4 cells (derived from a
primary lesion) and HN12 cells (derived from a lymph node metastasis). In addition,
identification of the signaling molecules regulating these processes and their respective
kinase activities were determined. Signal transduction effects seen in these cells due to
activation of the EPO/EPOR mechanism can further clarify the variability surrounding its
role in vivo. Previous reports showed that activation of signaling pathways, such as
MAPK, PI3-K/Akt, and JAK2/STAT5 leads to increased cellular proliferation and
invasion in other cancers as a result of EPOR expression in these cells(13,16,25,28,41,49). These
findings lead to the hypothesis that EPOR expression in HNSCC cells can increase the
potential of these cells to proliferate and migrate to surrounding tissues.

4.2 The HNSCC Model System
In order to effectively study EPO and EPOR in HNSCC and the signaling molecules
responsible for their effects, an in vitro approach was used.

In vitro studies of the

EPO/EPOR mechanism allow manipulations to be made to observe specific effects. Two
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different cell lines taken at different stages of HNSCC were obtained from the same patient
to avoid genetic variation. The HN4 cell line was taken from the patient from a primary
lesion site, and the HN12 cell line was obtained following metastasis to the lymph node.
To determine expression of EPOR in these cells, qRT-PCR analysis was performed in
several HNSCC lines as a preliminary experiment by our group. Of those cell lines
screened, HN12 showed the highest EPOR mRNA expression level when compared to the
others, a level about twice higher than HN4 EPOR expression obtained in the same
screening. MCF-7, a breast cancer cell line that has consistently been reported to express
EPOR and produce a biological response to EPO, was used as a point of reference when
considering expression levels in HN4 and HN12. HN12 was found to express EPOR at a
similar level to MCF-7. The low expression of EPOR in HN4 enabled it to be compared
with high EPOR-expressing HN12 cells in the following studies. This data, combined with
previous studies investigating the role of EPO in other cancers, proposes that EPO may
play an integral role in HNSCC progression through its interaction with EPOR, and
provides the foundation of the current study.
To investigate the role of EPO in these cells, it was first necessary to determine the
biological functionality of EPOR.

In order to test this, HN4 and HN12 cells were

subjected to RNA interference, and the EPOR gene was knocked down. Generation of two
EPOR knockdown constructs allowed comparison of these cells to control cells to test
contribution of the EPOR gene to various biological processes. Following knockdown of
EPOR, mRNA expression levels were confirmed with qRT-PCR in both HN12 and HN4
cells (Figures 12 and 13). The knockdown process was successful in both cells, with about
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a 60% decrease in EPOR expression HN12 shR16 cells and a 30% decrease in HN4 shR16
cells. The shR14 construct was downregulated more than 20% in HN12 cells, but only
about 10% in HN4 cells. It was concluded, therefore, that shR16 was the more efficient
shEPOR construct.

4.3 Role of EPO and EPOR in Proliferation
Several studies show the presence of EPOR in various cancers to promote tumor
cell survival and proliferation(1,13,25).

EPOR expression has been identified in breast

cancer, renal cancer, and melanoma, among others.

The potential for these cells to

proliferate can be affected by their ability to express EPOR. Results from the current study
support these findings in both HN4 and HN12 tumor cell lines. Cell proliferation was
decreased significantly in EPOR knockdown cells in HN4 and HN12 when compared to
the control (Figures 14 and 15). These results show a decrease in proliferation in these
cells as a consequence of EPOR suppression.
Knockdown of EPOR in these experiments can significantly downregulate
proliferation of HNSCC used in the current study without application of EPO. A recent
study reports overexpression of EPOR to be linked to increased breast cancer cell
proliferation, without EPO stimulation(13). This conclusion, along with the results obtained
in the current study, support the idea that EPOR may be constitutively activated and could
possibly be involved in an autocrine signaling mechanism in cancer. The effect that
exogenous EPO has on proliferation in HNSCC was motivation for the next stage of the
study.
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Administration of EPOGEN® (epoetin alfa), an ESA frequently given to anemic
cancer patients during treatment, to HN12 cells surprisingly had the opposite effect that
knockdown of EPOR produced in the prior experiments. A decrease in proliferation was
observed in response to increasing concentrations of EPOGEN® applied to HN12 control
cells in a dose-response experiment (Figure 16). A dosage of 1 U/mL-10 U/mL was
determined to be effective in downregulating growth in HN12 cells. Based on these
results, a concentration of 1 U/mL was applied in following experiments.

It was

concluded, therefore, that exogenous application of EPO can inhibit tumor proliferation in
HNSCC. The response EPO evoked in HN12 cell proliferation seemed to be independent
of the mechanism by which EPOR mediates growth of the cells, based on their opposite
effects. The results found in HNSCC differ greatly from several reports that show in vitro
application of EPO to enhance proliferation and colony formation in various
cancers(13,28,41,49).

The findings that expression of EPOR in HNSCC enhances

proliferation, and that application of exogenous EPO can simultaneously suppress
proliferation in the same cells are contradictory. These results suggest that these two
events observed in HNSCC proliferation may be independent from one another.
Restoration of HN12 proliferation by 50% was achieved with application of an
EPO-specific antibody in 1 U/mL EPOGEN® conditions against an IgG antibody (Figure
17). It was confirmed that 1 U/mL EPOGEN® was effective in consistently decreasing
proliferation in HN12 cells. Of greater importance was that EPO could now specifically be
designated responsible for decreasing cellular proliferation in this HNSCC cell line.
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We compared the role of EPO in HNSCC with the breast cancer line, MCF-7. Our
intention was to show differences in proliferative characteristics of these cancers in
parallel. MCF-7 is a form of breast cancer that has been studied extensively in its ability to
survive, grow, adhere, migrate, and invade via EPO/EPOR signaling. In addition to its
high expression of EPOR, its sensitivity to EPO can be high, according to previous
studies(13,25,41). Many reports show increased proliferation rates in response to EPO in
MCF-7, in addition to enhanced migration and invasion. This study produced similar
results, as MCF-7 proliferation was increased at a concentration of 10 U/mL EPOGEN®
(Figure 18). Concurrently, HN12 proliferation was suppressed as seen previously at a
concentration of 1 U/mL EPOGEN®.

The same concentration of EPO enhanced

proliferation in MCF-7 cells in a previous study with 10 U/mL(13). These cells were found
to be responsive at this concentration, whereas HN12 cell proliferation was affected at 1
U/mL with an even greater effect at 10 U/mL.
The responses EPOGEN® produced in HN12 and MCF-7 in the same experiment
showed us that usage of the drug in multiple cancer systems can differentially affect
cellular proliferation. From these results we can conclude that the ability of EPO to
suppress growth in HNSCC therefore differs from its role in proliferation of other cancers,
perhaps through activation of diverging signaling mechanisms.

According to these

findings, administration of EPO to patients with HNSCC who are suffering from anemia
can potentially remain as an attractive option for in vivo treatment if applied in an
appropriate and effective dosage.

81

4.4 Role of EPO and EPOR in Migration
Migration of tumor cells can lead to the spread of cancer from a localized area into
neighboring tissues and even distant sites, contributing to metastasis. When cancer cells
gain the ability to become mobile, survival rate for the patient decreases dramatically.
EPO has been shown to promote migration and invasion in breast cancer in vitro(13,25,41).
In addition to effect of EPO, one particular study shows that EPOR overexpression can
lead to increased migration in MCF-7(13).

We therefore performed scratch (wound-

healing) assays in HN4 and HN12 to determine if there is a difference in ability to migrate
in EPOR knockdown cells compared to their controls. After the scratch was performed,
potential for these cells to migrate back towards the center of plate was an effective
method to observe motility. Differences were not observed between the shEPOR cell lines
and the controls in both HN12 and HN4 (Figures 19 and 20). Furthermore, addition of 10
U/mL EPOGEN® in these cell lines did not produce a significant difference compared with
no application (Figures 22 and 23).
The potential for EPO and EPOR to produce a response in proliferation, but not in
migration of HNSCC compelled us to examine the specific signaling pathways that could
regulate survival, proliferation, and migration of these cells.

Perhaps one or more

signaling molecules associated with the EPO/EPOR mechanism can be activated to
produce distinct processes in HNSCC, effects that are dissimilar to other cancers studied.
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4.5 Pathway Activation Attributed to EPO/EPOR Association
Effects on survival, growth, and motility in cancer due to the effect of EPO and
presence of EPOR on the surface of these cells have been linked to several signaling
pathways. Included in these are the JAK2/STAT5 pathway, PI3-K/Akt pathway, and the
MAPK pathway. These pathways are not always distinct, but overlap, and often produce
similar responses to the other pathways. Perhaps one or more than one of these pathways
can be activated in a particular cancer. Effector molecules involved in these pathways
were tested for their ability to phosphorylate, which essentially determines their potential
to activate downstream targets. Although not as consistently associated with EPO/EPOR
signaling, the SAPK/JNK migration pathway was also evaluated as migration studies in
these cells were performed previously.
The kinase activity of STAT5, Akt, ERK, and JNK were tested in all cell lines with
western blot analysis (Figure 25). From these results, Akt kinase activity was found to be
upregulated in HN12 cells compared to HN4 cells. These findings could suggest the
possibility that Akt is further activated in the metastatic HN12 cell line due to its high
expression of EPOR when compared to HN4, which exhibits low EPOR expression.
Activation of Akt could also be responsible for the ability of HN12 cells to proliferate at a
faster rate than HN4. This is in agreement with the same study mentioned before in breast
cancer in which overexpressed EPOR produced increased Akt phosphorylation by a 1.6
fold increase compared to the vector control(13). Through its kinase activity, Akt can
inactivate many apoptotic inducer molecules such as BAD, enabling the cancer cells to
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survive and proliferate. Akt can also inhibit activation of anti-apoptotic molecules, i.e.,
Bim.
STAT5 and JNK did not show any kinase activity in this HNSCC model. Their ability
to phosphorylate in these HNSCC cells were considered too weak, even with higher
concentrations of antibody applied to the membrane. These pathways were concluded to
not be activated in this form of cancer, and may not be the molecules contributing to its
survival and growth based on these results. ERK did not show noticeable differences in
phosphorylation in between HN4 and HN12 cells, or between the control and knockdown
cells. It is possible that ERK also may not be responsible for the prior signal transduction
effects seen in these cells.
It can be concluded that pathway activation in different forms of cancer can also vary.
For instance, overexpression of EPOR produced increased phosphorylation of ERK as well
as Akt in breast cancer. Perhaps more beneficial would be to use a system to overexpress
EPOR to generate an increased signal response in the molecules tested in this study. These
overexpressed constructs are established, and ready to use for further experiments.
Effect of EPO on kinase activity of the same molecules was determined in HN12 and
MCF-7, the comparison previously conducted in a proliferation assay. p-ERK was found
to be downregulated with addition of 10 U/mL EPOGEN® in HN12 control cells. This
downregulation of ERK kinase activity may be accountable for the suppression of
proliferation observed in HN12 upon application of EPO, as seen previously. p-Akt,
seemed to be upregulated with addition of 10 U/mL EPOGEN® in MCF-7 cells, compared
to control conditions. This is consistent with other studies conducted in breast cancer in
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which Akt was phosphorylated in response to increasing concentrations of EPO(13,41). pERK was also found to be upregulated in 10 U/mL conditions in MCF-7 cells in the
current study. This finding also supports various breast cancer studies which have found
ERK

to

be

phosphorylated

with

increased

EPO

conditions(13,25,41).

Enhanced

responsiveness to EPO in MCF-7 could be due to high expression of EPOR (as shown in
Figure 11), although knockdown of EPOR in MCF-7 must be performed to confirm this.
Again, activation of JNK and STAT5 were not obtained in the current study. The JAK2STAT5 axis was also found to not be activated in MCF-7 cells in a previous study(13). It
can be concluded that the JAK2-STAT5 pathway may predominantly be responsible for
survival and differentiation in hematopoietic cells, and not in HNSCC and breast cancer.

4.6 Future Studies
In the current study, it was established that EPOR plays an integral role in
proliferation of HNSCC, also concluded by studies conducted in other cancers(13,28,30,39,52).
This was demonstrated through knockdown of the EPOR gene. It may be essential,
however, to observe how overexpression of EPOR can impact proliferation and possibly
evoke a migratory response in these cells. A possible future study could be to evaluate
how overexpression and downregulation of EPOR in parallel contribute to such biological
processes in HNSCC, as well as its response to EPO.

Migration assays could be

attempted, in addition to the proliferation and scratch assays conducted before, to
accurately predict how HN4 and HN12 cells move in vivo due to overexpression of EPOR.
Migration assays allow the cells to physically move through a semi-permeable membrane,
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and mimic mobilization of the tumor cells to other tissues. Overexpression of EPOR in
HNSCC may also produce an additional response in Akt kinase activity, or promote
activation of ERK, STAT5, and JNK, all of which can be measured by western blot. An
additional confirmation step to this experiment could be to apply specific pharmacological
inhibitors of the activated molecules in the overexpressed cells, and to observe any
changes in proliferation and migration as a result of their application.
Another function of EPO and EPOR is possible induction of angiogenesis, or
neovascularization of tumors(17).

To evaluate angiogenic potential of these cells,

expression levels of chemokines and cytokines most commonly associated with
angiogenesis (VEGF, CXCL5, CXCL8, EGF, etc.) can be tested with qRT-PCR in both
EPOR downregulated and EPOR overexpressed cells for comparison. Measurement of
angiogenesis can provide a more complete understanding of the role of EPO/EPOR in
HNSCC.
After these processes are confirmed in vitro, perhaps an in vivo approach to study
EPO/EPOR in a mouse model can be undertaken. Metastatic HN12 cells can first be
injected into the mice for growth of HNSCC. Administration of EPO to mice at an optimal
concentration can then be performed to monitor its impact on tumor size in these animals.
To confirm the effect of EPO in vivo, HN12 EPOR downregulated and overexpressed cells
can be tested to observe possible differences in tumor formation.
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4.7 Conclusions
The role of EPO and EPOR to stimulate differentiation and proliferation of RBCs is an
essential physiological process. The usage of EPO to treat cancer-related anemia in the
clinical setting can significantly improve QoL and survival rates in patients. It has been
implicated, however, by other studies as well as the current one that EPOR is present in
cancer cells and can contribute to their growth and spread, leading to tumor malignancy.
In this study it was shown that EPOR knockdown cells decreased HNSCC proliferation,
acknowledging its importance in promotion of cancer development. According to this
study conducted in HNSCC, the PI3-K/Akt signaling pathway seems to be activated to
achieve such proliferative effects through activation of EPOR. Application of exogenous
EPO, however, decreased proliferation in cells with normally expressing EPOR.
Therefore, it is possible that mere existence of EPOR in HNSCC can potentially increase
the risk of cancer progression without EPO, which may be regulated independently. In
addition, it was established that effects of EPO in HNSCC and breast cancer proliferation
were divergent, and that different dosages can generate dissimilar results. The responses
the drug can produce in vivo may therefore vary between cancers. Thus, it is crucial to
carefully monitor how EPO performs in patients among cancer types. The study of EPO in
the HNSCC model system provides a basis to further investigate the EPO/EPOR biological
mechanism for the management of cancer.
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